Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Brooks Michael J reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. President Michael J. Brooks reported an equity compensation award. He received 64,609 Common Shares in the form of restricted share units granted at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These restricted share units vest monthly in equal portions over thirty-six months starting on the grant date of May 27, 2026. Following this award, Brooks directly holds a total of 291,479 Common Shares.
Sistilli Carlo reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. director Carlo Sistilli reported an equity grant. He received 19,000 restricted share units of Common Shares at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date.
Following this award, Sistilli directly holds 49,417 Common Shares. Separately, 522 Common Shares are held indirectly through York-Cav Enterprises, Inc., which he partially owns and for which he disclaims beneficial ownership beyond his pecuniary interest.
Edesa Biotech director Charles V. Olson received an equity grant of 19,000 common shares on May 27, 2026. The shares were awarded at a price of $0.00 per share as a compensation grant, not an open market purchase. Following this transaction, Olson directly holds 30,000 common shares. According to the grant terms, these restricted share units will vest in equal portions over twelve months starting from the grant date, meaning the award converts into fully owned shares gradually over one year.
Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation grant and updated share holdings. He received 96,913 restricted share units of common shares at $0.00 per share, issued under the company’s 2019 Equity Incentive Compensation Plan. These units vest monthly in equal portions over 36 months, beginning on the grant date, and increase his directly held common shares to 729,463.
The filing also lists indirect holdings through several entities associated with him, including shares held by 1968160 Ontario Inc., The Digestive Health Clinic Inc., Pardeep Nijhawan Medicine Professional Corporation, and The New Nijhawan Family Trust 2015, where he is co-trustee. He disclaims beneficial ownership of these indirect positions except to the extent of his pecuniary interest.
Liu Da David reported acquisition or exercise transactions in this Form 4 filing.
Edesa Biotech, Inc. reported that director Da David Liu received a grant of 19,000 Common Shares in the form of restricted share units. The award was made at a stated price of $0.00 per share, reflecting equity-based compensation rather than a market purchase.
These restricted share units were granted under the company’s 2019 Equity Incentive Compensation Plan and will vest in equal monthly installments over twelve months starting from the grant date. Following this grant, Liu directly holds 24,501 Common Shares, showing a routine increase in his equity stake tied to compensation.
Edesa Biotech, Inc. reported results of its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved an amendment to the 2019 Equity Incentive Compensation Plan to increase shares available for issuance by 750,000 and remove the annual per-participant option grant limit.
All seven director nominees were elected to serve until the 2027 annual meeting, with support of roughly 2.67–2.71 million votes for each and 2,147,101 broker non-votes. Shareholders also approved, on an advisory basis, executive compensation and ratified MNP LLP as auditors for the fiscal year ending September 30, 2026.
The company reported that 4,901,921 common shares, or about 55% of shares entitled to vote, were represented in person or by proxy at the meeting.
Edesa Biotech, Inc. ownership update: Stonepine entities and Jon M. Plexico report beneficial ownership of 30,000 shares of Common Stock, representing 0.3% of the class.
The filing states the percentage is calculated based on 8,891,951 shares outstanding as of May 13, 2026. The reporting persons say the shares were not acquired to influence control and disclaim group membership.
EDESA Biotech filing an Amendment No. 2 to Schedule 13G/A reporting zero beneficial ownership. The filing states that as of 03/31/2026 Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed to beneficially own 0 Shares representing 0.00% of the outstanding Common Shares (CUSIP 27966L306).
The filing lists addresses for the issuer and the reporting persons and confirms that Nantahala is a Massachusetts limited liability company and that Harkey and Mack are U.S. citizens. Signatures by the reporting persons and the Chief Compliance Officer appear with a signature date of 05/15/2026.
Edesa Biotech Schedule 13G/A: Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen reported shared voting and dispositive power over 2 Common Shares of Edesa Biotech as of the close of business on March 31, 2026. The filing states the reporting persons directly own no Common Shares and reports 0% of the class.
The statement clarifies organizational relationships: Point72 Capital Advisors is general partner of Point72 Asset Management, Mr. Cohen controls both, and Cubist Systematic Strategies, LLC acts as a sub-adviser for a portion of the shares. Signatures by an authorized person appear dated May 15, 2026.
Edesa Biotech reports a Schedule 13G showing Rubric Capital Management and David Rosen beneficially own 687,500 Common Shares (7.74%). The filing states the holdings reflect 8,885,719 Common Shares outstanding as of March 30, 2026. The reported position is held by Rubric Funds with shared voting and dispositive power of 687,500 shares, and Rubric Long Term Opportunities Offshore Master Fund, LP is identified as having the right to receive dividends or sale proceeds on more than 5% of the class.